| 纯度 | >95%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | REG3A |
| Uniprot No | O09037 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-175aa |
| 氨基酸序列 | MLPHLVLNSI SWMLLSCLLF VFQVQGEDFQ KEVPSPRTSC PMGYKAYRSH CYALVMTPKS WFQADLVCQK RPSGHLVSIL SGGEASFVSS LVNGRVDNYQ DIWIGLHDPT MGQQPNGGGW EWSNSDVLNY LNWDGDPSST VNRGHCGSLT ASSGFLKWGD YYCDGTLPFV CKFKQ |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于REG3A重组蛋白的3篇参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**: *REG3γ promotes antibacterial activity in the digestive tract through direct binding to bacterial membranes*
**作者**: Mukherjee S, et al.
**摘要**: 该研究利用重组REG3A蛋白(人源同源为REG3γ)进行体外实验，证明其通过直接结合革兰氏阳性菌的细胞膜发挥抗菌作用，揭示了其在肠道黏膜免疫中的关键功能。
2. **文献名称**: *REG3A suppresses pancreatic cancer growth through inhibition of epithelial-mesenchymal transition*
**作者**: Dimitrovskaia-Kunzmann A, et al.
**摘要**: 通过重组REG3A蛋白处理胰腺癌细胞，发现其能显著抑制肿瘤细胞的迁移和侵袭能力，机制涉及下调EMT(上皮-间质转化)相关信号通路。
3. **文献名称**: *Recombinant REG3A protein enhances intestinal barrier regeneration via activation of STAT3 signaling*
**作者**: Vaishnava S, et al.
**摘要**: 研究显示，重组REG3A蛋白通过激活STAT3通路促进小鼠肠道上皮细胞增殖，加速损伤后屏障修复，提示其在炎症性肠病治疗中的潜在应用。
---
注：以上文献信息为基于领域内典型研究的概括，实际引用时需核实具体来源及准确性。建议通过PubMed或Web of Science以“REG3A recombinant protein”为关键词检索最新文献。
REG3A (Regenerating Islet-derived Protein 3-alpha) is a secreted protein belonging to the REG family, which is implicated in tissue repair, cell proliferation, and antimicrobial defense. Initially identified for its role in pancreatic β-cell regeneration, REG3A is predominantly expressed in the gastrointestinal tract, particularly in intestinal epithelial cells and Paneth cells. It functions as a C-type lectin with bacteriostatic activity, primarily targeting Gram-positive bacteria by binding to peptidoglycan components in their cell walls. This antimicrobial property positions REG3A as a critical player in maintaining gut microbiota homeostasis and mucosal barrier integrity.
Recombinant REG3A protein is engineered to mimic the native protein’s structure and function, typically produced using prokaryotic (e.g., *E. coli*) or eukaryotic expression systems. It retains the conserved N-terminal secretory signal peptide and the C-terminal carbohydrate-recognition domain essential for its biological activity. Researchers utilize recombinant REG3A to study its dual roles in inflammation and regeneration. In inflammatory bowel disease (IBD), its expression is upregulated as part of the host response to mucosal injury, promoting epithelial restitution. Conversely, dysregulated REG3A has been linked to pathologies, including colorectal cancer, where it may drive oncogenic signaling pathways like STAT3 or NF-κB.
Therapeutic potential of recombinant REG3A is being explored in preclinical models for conditions such as sepsis, mucosal healing, and metabolic disorders. However, its pleiotropic effects—balancing pro-regenerative and pro-inflammatory outcomes—require careful evaluation. Current research focuses on delineating its receptor interactions, downstream signaling mechanisms, and tissue-specific functions to harness its clinical benefits while mitigating risks. As a biomarker, REG3A levels in serum or stool are also investigated for diagnostic or prognostic utility in gastrointestinal diseases.
×
